[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epithelial-ovarian-cancer-fallopian-tube-or-peritoneum\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epithelial-ovarian-cancer-fallopian-tube-or-peritoneum":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100638813","phase-1-dual-target-car-nk-cells-in-recurrent-or-refractory-epithelial-ovarian-cancer-100638813",false,"NCT07589543","Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer","A Phase 1\u002F2, Open-Label, Dose-Escalation and Expansion Study of Dual-Target CAR-NK Cells (EB-DUALNK) Following Lymphodepleting Chemotherapy in Adults With Recurrent or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma","EB-DUALNK-OV","Inclusion Criteria:\n\n* Age 18-75 years; able to provide written informed consent.\n* Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma that is recurrent or refractory after standard therapy (at least 2 prior systemic regimens), with measurable disease per RECIST v1.1 and ECOG performance status 0-1.\n* Tumor tissue available for antigen assessment. Participant must meet protocol-defined positivity for the selected dual-target pair (example: 1 target expressed in \\>=50% of tumor cells by IHC and the second target in \\>=20%).\n* Adequate organ function per protocol-specified labs; negative pregnancy test nd agrees to use effective contraception for a protocol-defined period after infusion.\n\nExclusion Criteria:\n\n* Active CNS metastases or carcinomatous meningitis (unless treated and stable for a protocol-defined period).\n* Prior gene-modified cell therapy targeting any of the study antigens (GD2, MUC1, PSMA, mesothelin) within 6 months.\n* Uncontrolled active infection (including uncontrolled HIV, HBV, or HCV) or active systemic fungal infection.\n* Clinically significant cardiovascular disease (e.g., recent myocardial infarction, unstable angina, uncontrolled arrhythmia) or LVEF \\\u003C50% .\n* Active autoimmune disease requiring systemic immunosuppression within 14 days prior to lymphodepletion (physiologic steroid replacement permitted).\n* History of organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Pregnant or breastfeeding.\n* Any condition that, in the investigator's judgment, would compromise participant safety or compliance.","FEMALE","18 Years","75 Years",{"count":21,"type":22},42,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial ovarian cancer. Candidates for targeting include GD2, MUC1, PSMA, and mesothelin. After baseline biomarker assessment (tumor antigen expression), the program will select the most suitable dual-target pair for clinical testing. Participants will receive lymphodepleting chemotherapy followed by EB-DUALNK infusion and safety\u002Fresponse follow-up.",[29,30],"Epithelial Ovarian Cancer","Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum",[32,33,34,35,36,37,38,39,40,41],"Solid tumor","Ovarian cancer","Immunotherapy","Adoptive cell therapy","CAR-NK","Dual-target","GD2","MUC1","PSMA","Mesothelin","RECRUITING","2026-05-10",{"date":45,"type":46},"2026-05-15","ACTUAL",{"date":48,"type":46},"2026-03-02",{"date":50,"type":22},"2028-03-17",{"name":52,"class":53},"Beijing Biotech","INDUSTRY",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100580525","parpi-and-ovarian-cancer-survival-100580525","NCT06838429","PARPi and Ovarian Cancer Survival","Effect of PARP Inhibitors Maintenance Therapy on the Survival Rate of Advanced or Relapsed Epitherlial Ovarian Cancer: an Observational Cohort Study","Inclusion Criteria:\n\nGroup 1:\n\n* Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December 2024.\n* Complete data on first-line treatment and maintenance therapy.\n* Availability of follow-up data.\n\nGroup 2:\n\n* Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December 2024.\n* Disease progression occurring at least 6 months after the completion of the last platinum-based chemotherapy regimen.\n* Complete data on second-line treatment and maintenance therapy.\n* Availability of follow-up data.\n\nExclusion Criteria:\n\nGroup 1:\n\n* Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.\n* Missing first-line or follow-up data.\n\nGroup 2:\n\n* Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.\n* Patients with second relapse.\n* Platinum-resistant patients, such as those who had disease progression during chemotherapy or within 6 months after platinum-based chemotherapy.\n* Missing second-line or follow-up data.","80 Years",{"count":64,"type":22},6000,"OBSERVATIONAL","With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.",[30,68],"PARP Inhibitor","NOT_YET_RECRUITING","2025-02-17",{"date":72,"type":46},"2025-02-20",{"date":74,"type":22},"2025-03",{"date":76,"type":22},"2026-03",{"name":78,"class":79},"Shanghai Gynecologic Oncology Group","OTHER_GOV"]